RecruitingPhase 2NCT06114225

Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial

Studying Osteosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Principal Investigator
Weibin Zhang, PhD, MD
Ruijin Hospital
Intervention
metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy(combination_product)
Enrollment
43 enrolled
Eligibility
10-65 years · All sexes
Timeline
2023 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06114225 on ClinicalTrials.gov

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Osteosarcoma →

← Back to all trials